Anti-IL-6 therapy is typically initiated at the onset of grade 2 CRS, with a substantial portion of patients requiring intensive care unit (ICU) support upon the emergence of grade 3 toxicities [89]. Here, IL6 is linked to congenital rubella syndrome.